MedTrace Logo

Menopur And Rekovelle Combination Study

NCT03483545 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2019-08-28

No results posted yet for this study

Summary

This study proposes to evaluate the effect of adding HP-hMG (Menopur) to follitropin delta in a "mixed protocol" regimen, using an individualized, fixed dose of follitropin delta based on the established algorithm, combined with a variable, adjustable dose of Menopur based on body weight and ovarian reserve.

Conditions

  • Fertility Disorders

Interventions

COMBINATION_PRODUCT

Follitropin delta and HP-hMG

Follitropin delta dose will be determined by AMG and weight in Kg. Highly purified human menopausal gonadotrophin will be determined by follitropin delta dose and body weight in Kg

Sponsors & Collaborators

  • Create Fertility Center

    collaborator OTHER

  • Olive Fertility Centre

    collaborator OTHER

  • Hannam Fertility Centre

    collaborator UNKNOWN

  • Dr François Bissonnette

    lead INDUSTRY

Principal Investigators

  • François Bissonnette, MD · Clinique Ovo

  • Clifford Librach, MD · CReATe Fertility Centre

  • Tom Hannam, MD · Hannam Fertility Centre

  • Al Yuzpe, MD · Olive Fertility Centre

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-17
Primary Completion
2019-07-31
Completion
2019-07-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03483545 on ClinicalTrials.gov